The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Akero Therapeutics, Inc(NASDAQ:AKRO) 
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protec...
Website: http://www.akerotx.com
Founded: 2017
IPO Price: $16 (Jun 20, 2019)
Full Time Employees: 16
CEO: Andrew Cheng
Sector: Healthcare
Industry: Biotechnology
Akero Therapeutics Days Payable Outstanding ttm (DPO)
Akero Therapeutics Op Cashflow Per Share ttm
Akero Therapeutics Free Cashflow Per Share ttm
Akero Therapeutics Cash Per Share ttm
Akero Therapeutics P/S ratio ttm
Akero Therapeutics (GAAP) P/E ratio ttm
Akero Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.